RITHCLAR™ 125
Clarithromycin 125mg each 5 ml with water
Quick Facts
Key Benefits
Mechanism of Action
Clarithromycin 125mg/5mL dry syrup — paediatric liquid formulation of clarithromycin, same 50S ribosomal subunit binding mechanism blocking translocation in susceptible organisms. At 125mg/5mL, calibrated for weight-based paediatric dosing (7.5mg/kg twice daily) in children approximately 10–30 kg. Provides superior acid stability and tissue penetration compared to erythromycin, covering Mycoplasma, Chlamydia, and atypical respiratory organisms alongside standard ENT pathogens. See RITHCLAR™ 250 for full mechanism detail.
Indications
Paediatric community-acquired pneumonia with suspected atypical organisms (Mycoplasma, Chlamydia), acute otitis media (alternative to amoxycillin in penicillin-allergic children), pharyngitis and tonsillitis, and acute sinusitis. Preferred over erythromycin suspension for paediatric use due to twice-daily dosing and superior gastric acid stability. H. pylori eradication in paediatric patients as part of triple therapy.
Dosage & Administration
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Why RITHCLAR™ 125?
RITHCLAR™ 125 Dry Syrup completes the RITHCLAR™ brand family with a paediatric liquid formulation — enabling prescribers to maintain brand continuity from paediatric to adult patients within the same Seclis Labs macrolide range. The 14-day post-reconstitution stability is a practical advantage over competitor products requiring 7-day discard.
